Figure 1.
PBMT reduces cerebral Aβ levels and amyloid plaque burden in APP/PS1 transgenic mice. (a–d) Cerebral cortex and hippocampus Aβ measurements were performed by ELISA. APP/PS1 mice (n = 7) under PBMT treatment showed dramatic reductions in the levels of soluble Aβ1‐40 (a) and Aβ1‐42 (b), insoluble Aβ1‐40 (c) and Aβ1‐42 (d) compared with control transgenic mice (n = 7). (e) Representative images immunostained with Aβ‐specific 6E10 antibody in the brain of PBMT‐treated WT and APP/PS1 mice (n = 5). Scale bar: 300 μm. (f) Representative images of thioflavin T‐stained senile plaques in the brains of different groups of mice (n = 5). Scale bar: 300 μm. (g) The values in the bar graph are expressed in the percentage area occupied by diffuse plaques and fibrillar plaques. All the data are reported as mean ± SEM. *p < 0.05 and **p < 0.01 versus the control group; #p < 0.05 versus the indicated group